Protalix BioTherapeutics (PLX) Inventory Average (2011 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Inventory Average of $28.1 million for Q1 2026, up 37.92% year-over-year from $20.4 million in Q1 2025, and up 19.62% quarter-over-quarter from $23.5 million in Q4 2025.
Protalix BioTherapeutics (PLX) Inventory Average (2011 - 2026) Analysis & Trends
Protalix BioTherapeutics' Inventory Average history runs 15 years deep, the most recent figure standing at $28.1 million for Q1 2026.
- In Q1 2026, Inventory Average rose 37.92% year-over-year to $28.1 million; the TTM figure through Mar 2026 stood at $28.1 million (up 37.92% YoY), while the FY2025 annual figure was $23.5 million, up 16.59% from the prior year.
- Inventory Average for Q1 2026 stood at $28.1 million, up from $23.5 million in the prior quarter.
- The five-year high for Inventory Average was $28.1 million in Q1 2026, with the low at $15.5 million in Q3 2022.
- The 5-year median for Inventory Average is $20.3 million (2023), against an average of $19.9 million.
- The sharpest annual moves came in 2024 and 2026: Inventory Average fell 8.01% in 2024, then surged 37.92% in 2026.
- Protalix BioTherapeutics' Inventory Average stood at $15.7 million in 2022, then climbed by 29.53% to $20.3 million in 2023, then dropped by 5.38% to $19.2 million in 2024, then rose by 22.22% to $23.5 million in 2025, then increased by 19.62% to $28.1 million in 2026.
- Business Quant data shows PLX's Inventory Average at $28.1 million in Q1 2026, $23.5 million in Q4 2025, and $21.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 213.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 707.10 Mn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 90.57 Mn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 196.36 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 137.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Protalix BioTherapeutics | 192.37 Mn | 151.71 Mn | 12.13 Mn | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.38 Mn |
| Mar 31, 2026 | 28.10 Mn |
| Dec 31, 2025 | 23.49 Mn |
| Sep 30, 2025 | 21.19 Mn |
| Jun 30, 2025 | 20.32 Mn |
| Mar 31, 2025 | 20.37 Mn |
| Dec 31, 2024 | 19.22 Mn |
| Sep 30, 2024 | 18.96 Mn |
| Jun 30, 2024 | 21.53 Mn |
| Mar 31, 2024 | 20.70 Mn |
| Dec 31, 2023 | 20.31 Mn |
| Sep 30, 2023 | 20.61 Mn |
| Jun 30, 2023 | 19.97 Mn |
| Mar 31, 2023 | 18.55 Mn |
| Dec 31, 2022 | 15.68 Mn |
| Sep 30, 2022 | 15.53 Mn |
| Jun 30, 2022 | 16.55 Mn |
| Mar 31, 2022 | 17.27 Mn |
| Dec 31, 2021 | 16.34 Mn |
| Sep 30, 2021 | 14.19 Mn |